section is connected to higher risk of asthma. 4, 5 A connection between early-life microbiota composition and atopy has been reported, 6, 7 and non-allergic children's microflora has been shown to be more diverse. 8 The presence of probiotic bacteria in the intestinal microflora during the first year of life is connected to less allergic morbidity up to 2 years of age. 9 Probiotics are defined as "live microorganisms which when administered in adequate amounts, confer a health benefit on the host" (Food and Agricultural Organisation). In a large observational cohort study of over 40 000 participants, consumption of probiotic milk products in pregnancy and infancy was associated with a slightly reduced risk of atopic eczema at 6 months and reduced rhinoconjunctivitis at 18-36 months. There was no association with asthma. The information about the probiotic usage was based on self-report. The probiotics used were three dairy products, Biola milk, Biola yoghurt and Cultura milk, 10 which contained Lactobacillus acidophilus (LA-5).
It has been shown in several studies that probiotics given preand postnatally prevent eczema for up to 2 years of age. [11] [12] [13] In longer 6-year follow-up studies, an allergy-reducing effect has been reported in some 14, 15 but not all studies. 16 Kalliomäki et al 17 reported less atopic eczema for up to 7 years. Other 7-to 8-year follow-up studies have shown no effect. 18, 19 In previous phases of our study, the largest probiotic intervention trial reported to date, we found 29% less atopic disease at 2 years of age in the group receiving probiotics in the perinatal period. 20 In the 5-year follow-up, there was no statistically significant difference in the whole cohort, but the Caesarean-delivered children in the probiotic group had significantly less IgE-associated allergy. 21 At 10 years of age, the reducing effect on eczema was still visible, and surprisingly, allergic rhinoconjunctivitis was increased at 5-10 years. 22 The objective of this follow-up was to investigate the effect of perinatal probiotic intervention on the prevalence of allergic diseases and sensitization at 13 years of age.
| ME TH ODS
Pregnant women carrying a child at a high risk of allergy were recruited for the trial. The criterion for high allergy risk was that at least one of the parents had had doctor-diagnosed asthma, allergic rhinitis or atopic eczema. The participants (n = 1223) were randomized to receive a preparation of four probiotics or placebo in a dou- Mothers in the placebo group received capsules containing microcrystalline cellulose, and the infants received the contents of the same capsules, with no oligosaccharides (Table 1) . The capsules and syrups used in the trial looked, smelled and tasted identical.
The viability of the bacteria was regularly controlled. The use of non-study probiotic products (Table 2) was not restricted after the intervention phase. Exclusion criteria were birth at less than 37 weeks of gestation, major malformations and the second born of twins.
Compliance with the intervention was controlled at 3-and 6-month visits by questioning about the amount of doses not given and by counting the returned unused capsules. The 80% compliance level for the 180-day intervention was reached by 87% in the probiotic group and 88% in the placebo group. During their early years, the children were examined by a paediatrician at 6 months, 2 and 5 years and questionnaires concerning symptoms of allergic or infectious disease and related environmental factors were assessed annually up to five years. 20 After the 5-year visit, the participants' parents and study staff were unblinded. Study of Asthma and Allergies in Childhood (ISAAC) Questionnaire for 13-to 14-year-old children. 23, 24 The questionnaire includes questions about wheezing and coughing, sneezing, a runny or blocked nose, and eczema symptoms. Participants were asked to report the frequency of wheezing attacks over the past 12 months and the frequency of night wheezing in the questionnaire (Section 7.2 in the original questionnaire 25 ). For the purpose of these analyses, wheezing attacks were dichotomized as "no attacks" and "one or more attacks" in the past 12 months. Night wheezing was dichotomized as "Less than one night a week" and "One or more nights per week".
Our research is not part of the ISAAC collaboration.
The primary outcome variable was doctor-diagnosed allergic disease (eczema, asthma, rhinitis, food allergy). A combination of questionnaire answers was used to define the presence of allergic illness during the previous 12 months. A symptom-report-based diagnosis of eczema was made if three specific questions were answered affirmatively, that is, "Have you ever had an itchy rash which was coming and going for at least 6 months?", "Has this itchy rash at any In this table, n (probiotic) = 330, n (placebo) = 312. Statistically significant differences (P < 0.05) are marked in bold.
Pearson's chi-squared test was used to compare categorical vari- 
| RESULTS
In the initial phase of the study, there were 1018 intention-to-treat infants. A total of 642 participants (63.1%) completed the questionnaire at the 13-year follow-up, with 330 children from the probiotic group and 312 from the placebo group. The demographic characteristics of the groups were similar (Table 1) . Among those who provided a blood sample (n = 459), 43.7% had a household dog or cat at 13 years of age, compared to 32.9% of the subgroup who did not provide a blood sample (P = 0.010). There were no other significant differences between these two groups (Supporting Information Table A1 ). In vaginally delivered subgroup, 73.4% were breastfed for 6 months or more, compared to 63.3% in Caesareandelivered subgroup (P = 0.036). Mothers' average age was 31.07 years in vaginally delivered and 32.57 years in Caesareandelivered group (P = 0.002). No other variables had significant differences between these two groups (Supporting Information Table   A1 ). Participants of the 13-year follow-up were compared to others in the intention-to-treat group. Infants, who dropped out in the early phase (64), had to be ignored in the analysis due to missing data. The others had no significant differences in the available variables compared to participants of the 13-year follow-up (Supporting Information Table A1 ). The average age at the day of attending the study was 12.9 years, with only a 7-day difference between the probiotic and placebo groups. The prevalence of allergic disease at 5 years of age did not differ significantly between the cohort participating in the 13-year follow-up and those who did not participate (data not shown).
At 0-2 and 3-5 years of age, the continuous consumption of non-study probiotics did not differ significantly between the probiotic and placebo groups (Table 2 ). In the 13-year follow-up, there was no significant difference in daily use of probiotics between the groups (9.7% in the probiotic group and 6.7% in the placebo group, P = 0.172), but more participants in the probiotic group reported using probiotics weekly (16.1% vs 10.6%, P = 0.041) during the previous 12 months. These non-study products contained mainly L.
rhamnosus GG or Lactobacillus reuteri.
Among the primary clinical outcomes (Table 3) , no statistically significant differences were found in the prevalence rates of doctor-diagnosed allergic disease (55.2% in the probiotic group and 59.0% in the placebo group, P = 0.328) or any allergic disease with IgE sensitization (42.7% and 39.9%, P = 0.547). Regarding the secondary clinical outcomes (Table 3) , no statistically significant differences between the groups were found in the prevalence rates of doctor-diagnosed asthma (12.7% and 17.0%, P = 0.129), eczema (31.8% and 35.6%, P = 0.314), food allergy (22.7% and 26.9%, P = 0.218) or food-specific sensitization (21.5% and 19.2%, P = 0.543). However, the presence of inhalant-specific IgE sensitization (>0.7 kU/L) was 59.3% in the probiotic group and 49.8% in the placebo group (P = 0.040). There were no differences in the prevalence rates of individual allergic diseases as assessed by use of the ISAAC questionnaire (Table 3) .
No significant differences between the probiotic and placebo groups were found as regards specific sensitization to birch, timothy grass, mugwort, cat dander, dog dander, egg white, milk or peanuts | 509 variables of the study. For the P-values of these eight outcomes,
Holm method was applied, and the difference in ISAAC-based allergic disease in Caesarean-delivered subgroup is considered significant.
When the same analysis is applied on all P-values on Tables 3 and 4, none of them are significant.
We also carried out an additional analysis for the primary and secondary clinical outcomes, where missing values where imputed from 10-year follow-up. Sensitization was not analysed at 10-year follow-up, and sensitization-related outcomes could not therefore be included in this analysis. There were no statistically significant results in the whole cohort (n = 838). In the Caesarean-delivered subgroup (n = 144), the prevalence of any allergic disease in 12 months (ISAAC) was 44.1% in probiotic group and 61.8% in placebo group (P = 0.033). There were no other significant differences.
Although the prevalence of asthma did not differ significantly in the whole cohort or in the aforementioned subgroups, wheezing attacks during the previous 12 months were reported by 8.5% of the probiotic group and 14.7% of the placebo group. A breakdown of the responses to asthma-related ISAAC questions is presented in Table 5 . Wheezing attacks during the previous 12 months represented the only variable with a significant difference.
There was no significant difference in average SCORAD scores in the whole cohort (n = 470, 1.94 in the probiotic group and 2.33
in the placebo group, P = 0.214) or in the Caesarean-delivered subgroup (n = 79, 2.26 in the probiotic group and 2.17 in the placebo group, P = 0.701). In the whole cohort, 13.5% of the participants in the probiotic group and 17.4% of the participants of the placebo group had SCORAD higher than 0 (P = 0.253). In the Caesarean-T A B L E 3 Allergic disease and sensitization in the probiotic and placebo groups at 13 y Any specific food IgE level >0.7 kU/L. delivered subgroup 13.5% of the probiotic group and 19.0% of the placebo group had SCORAD higher than 0 (P = 0.508).
Growth was similar in the two groups (Supporting Information   Table A2 ). Essential haematological values were normal in the study population, and there were no statistically significant differences between the groups (Supporting Information Table A3 ). There were no statistically significant differences in PEF measurements. The 
| DISCUSSION
Early probiotic treatment did not show an overall preventive effect on doctor-diagnosed allergic diseases in 13-year follow-up. However, in the Caesarean-delivered subgroup, a statistically significant effect was observed in the incidence of any allergy, and eczema, as reported in the ISAAC questionnaire. Analysis of the Caesareandelivered subgroup was not preplanned in the original study protocol. It should also be noted that in this study design, the birth mode is a post-randomization variable. There was no significant difference in SCORAD scores between probiotic and placebo groups. An important motivation behind this follow-up study was to investigate the possible effect of probiotic treatment on airway allergies, which mostly become manifest in later childhood. The probiotic group We have reported numerous comparisons with p-values. Holm method was applied to address this issue. However, it must be taken into an account that many of our outcome variables are interconnected due to the way they are calculated and they have also a strong clinical interconnection. Consideration is needed, when evaluating this statistical analysis. To our knowledge, this is the longest follow-up period in a probiotic allergy prevention trial with sensitization analysis. The size of our cohort is still good 13 years after the intervention.
Sensitization analysis provided valuable information to accompany the questionnaire data. Increased sensitization was observed in the probiotic group of the whole cohort, but not in the Caesareandelivered subgroup. On the basis of the results of our study, the development of sensitization and that of allergic disease was surprisingly divergent. Probiotic treatment increased sensitization and showed some tendency to result in less allergic disease in the whole cohort-and significant reduction in allergic disease was observed in a Caesarean-delivered subgroup. In a study by Kalliomäki et al, 17 a reduction in atopic eczema persisted at 7-year follow-up, but sensitization was not reduced. It may be speculated, as has been proposed by Dotterud et al, 13 that the protective probiotic effect is not related to sensitization, but may be related to an anti-inflammatory mechanism. The development of sensitization is also different between different strains. In one cohort where L. acidophilus (LAVRI-A1) was used, the probiotic group had higher sensitization compared to placebo group at 1 year of age. There was no difference in 2.5 years or at 5 years, which implies that L. acidophilus seems to prepone the development of sensitization. [26] [27] [28] In our cohort, colonization of probiotic strains was observed at 6 months, but not anymore at 2 years of age. 20 Beneficial findings were seen in the Caesarean-delivered subgroup, where the prevalence of eczema was 18.9% in the probiotic group and 37.5% in the placebo group. This is in line with previous results from our cohort. In the 5-year follow-up, Caesarean-delivered children in the probiotic group had significantly fewer IgE-associated allergies and less IgE-associated eczema. 21 The prevalence of allergic diseases was very high in this high-risk cohort (55.2% vs 59.0%), which makes it convenient for observing possible preventative effects. However, the prevalence of allergic diseases was similar compared with that in another Finnish long-term follow-up study of high-risk cohorts, 29 where the overall prevalence of allergic disease was 56.4% in probiotic groups and 46.6% in placebo groups. In one
Norwegian perinatal prevention trial involving use of a probiotic mixture containing L. rhamnosus GG, L. acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12, an effect on atopic dermatitis was seen mainly in children with non-atopic parents but not in children with atopic parents. 13 In previous literature, no significant differences have been found in lung-function measures, asthma or rhinitis in probiotic prevention trials. [17] [18] [19] In our study, we found fewer wheezing attacks in the probiotic group during the previous 12 months, but no effect on asthma prevalence. The same applies in a systematic review, where no protective association was found between perinatal use of probiotics and doctor-diagnosed asthma or childhood wheezing. 30 The participation rate in the study (63.1%) was good considering the long follow-up period. At 5-year follow-up, the participation rate was 87.5%. The demographic characteristics of the groups were similar. There was no difference in daily use of probiotics at 13 years, but weekly use was somewhat more common in the probiotic group.
Most importantly, there was no difference in the use of (non-study) probiotics during the early years (0-2 years) or at 3-5 years. It is believed that the microbiota and the immune system are most amenable to intervention by probiotics in the first year of life. Probiotics are already widely consumed, and the results of the trial could have possibly been more pronounced, without non-study probiotic usage.
Probiotic products are commonly used, but regular daily use is rare in our population. In our study, probiotic treatment started before birth and continued for 6 months in infancy. Different timings and modes of administration (to breastfeeding mother or infant directly) have to be considered when further studying the matter.
According to a review published in 2017, neither prenatal, postnatal In this table, n (probiotic) = 330, n (placebo) = 31. Statistically significant differences (P < 0.05) are marked in bold.
nor pre-and postnatal treatment is consistently effective in different study designs. 12 The strongest results, however, have been seen in studies with prenatal maternal administration and postnatal supplementation directly to the infant. 11, 20, 31 In one prenatal study with Lactobacillus GG, no effect on eczema was found. 32 The authors presented a strong argument that probiotic treatment limited to the prenatal period is not effective for preventing eczema, or at least that Lactobacillus GG is not suitable for the purpose. In one study carried out in Sweden, the treatment period lasted from 4 to 13 months of age, targeting the weaning period. 19 In that study, no long-term effect on any diagnosed allergic disease, airway inflammation or IgE sensitization was found.
The viability of the used probiotic product is important. In one treatment study stopped in the pilot phase, heat-inactivated LGG was associated with adverse gastrointestinal symptoms and diarrhoea. The viable LGG used by the comparison group in the same study showed a tendency to lead to a decrease in SCORAD scores. 33 In our study and in the majority of all studies in this field, a viable probiotic product has been used. In our cohort, we also tested for the presence of the probiotic strains in the faeces of the participants at birth, and at three, six and 24 months of age. 21 The prevalence of the probiotic bacteria was significantly higher in the probiotic group than in the placebo group at 6 months of age. 20 World Allergy Organization guidelines (2015) suggest probiotics for pregnant women, breastfeeding women and for infants, when the child has a high risk for allergy. The benefit is considered to come mainly from preventing eczema. 34 Pre-and postnatal probiotic intervention appears to be the most effective, and it has also been proposed that the question of the diversity of microbiota is multigenerational in wider sense. Correct selection of the probiotic strain is also important, and there is evidence concerning different effectiveness of the various probiotic strains. In a study with two treatment arms, L. rhamnosus HN001 was associated with a protective effect against eczema, but no effect was found as regards B animalis subsp. lactis HN019. 31 In conclusion, probiotic treatment did not reduce the prevalence of allergic disease in the whole cohort in our 13-year follow-up study in a high-risk population. However, in the Caesarean-delivered subgroup, probiotics had a protective effect against any allergic disease and eczema, based on ISAAC questionnaire responses. Caesareandelivered children appear to benefit more from affected maturation of the microbiota. It is quite commonly assumed, that the passage through birth canal is important in constituting the neonatal microbiome with the vaginal and stool bacteria, and therefore explains the Caesarean-delivered children's higher risk for allergic diseases. This view has, though, been strongly criticized 35 and requires further investigation. Nevertheless, it is well known that vaginally and Caesarean-delivered children have different microbiota composition during infancy. 36 It is intriguing that the effect of early intervention is so strong that it is still detectable at the age of 13 years. The prevalence of allergic disease was high, and the consumption of non-study probiotic products after the trial phase was common but irregular.
Further investigation is needed to confirm the long-term effect of probiotic intervention in different populations and to identify the most effective probiotic strains, synbiotic combinations and timing of administration.
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